Lilly is putting $6.5 billion into concrete and up to $1 billion into AI drug discovery

The market marked Lilly's AI partner at $40 billion this week

On October 8, Isomorphic LabsPVT$600M — Isomorphic Labs, private, latest valuation $600M, the Alphabet▲+1.75% — Alphabet, up 1.75 percent today majority-owned spinout that counts Eli Lilly▲+0.24% — Eli Lilly, up 0.24 percent today among its pharma partners, was reported in early talks to raise at $40 billion to $50 billion, up from roughly $17.5 billion in May after a $2.1 billion Series B ¹². Isomorphic has never dosed a patient; first-in-human trials are targeted by the end of 2026 ¹². Its deals with Lilly, Novartis and Johnson & Johnson carry more than $3 billion in potential milestones, payable only on development success ¹. The risk lands on anyone pricing Lilly's AI optionality at private-market rates: the $40 billion mark belongs to a private company Lilly does not own, and Lilly's own spend on the same thesis stops at $1 billion.

Lilly answered with $6.5 billion of concrete

On September 21, Lilly broke ground outside Houston on a $6.5 billion plant↗ to make the active ingredient for Foundayo, its oral GLP-1 pill: roughly 4,000 construction jobs, more than 600 permanent ones, and the tenth US manufacturing site Lilly has announced since 2020 ³⁴⁵. Texas Governor Greg Abbott called it the largest active-pharmaceutical-ingredient project in the state's history ³. Foundayo is approved in the US, under review in more than 40 countries, and slated for a full global rollout in 2027 ³⁴.

Mounjaro's $9.9 billion a quarter underwrites the concrete

The engine paying for it is Mounjaro, the world's top-selling drug: $9.9 billion last quarter alone, nearly $23 billion across 2025, and more than a third of Lilly's total sales ⁶⁷. Quarterly revenue has more than doubled since late 2023 while quarterly capital spending tripled, to $2.9 billion ⁸. The franchise carries its own exposure: a North Carolina man sued Lilly this month, claiming Mounjaro and Trulicity left him with stomach paralysis↗ ⁶.

Lilly's AI budget is one line, at most $1 billion over five years

The week's AI headlines rest on a number that has not changed since January 12: up to $1 billion over five years↗, co-invested with Nvidia▼−0.36% — Nvidia, down 0.36 percent today in a Bay Area lab running on BioNeMo and the coming Vera Rubin chips ⁹. "Up to" is a ceiling, not a check. Nvidia's win is positional: if BioNeMo and Vera Rubin become the default stack for biology models at a drugmaker of Lilly's scale, the chipmaker holds the reference design for pharma's AI labs ⁹. Lilly pays for AI like an option and for factories like a certainty. Its own shelf priced softer: TRex Bio, a Lilly-backed autoimmune biotech, raised $116.7 million at $14 a share↗, the bottom of its range ¹⁰.

Three catalysts will settle the ledger

Foundayo's next clinical data, in diabetes and sleep apnea, lands later this year ⁴. Isomorphic's first-in-human trial is due by the end of 2026 ¹². Foundayo's global rollout follows in 2027 ³. Until then, the ledger reads $6.5 billion of concrete and, at most, $1 billion of code.